{"denoms":[{"counts":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"54"}],"units":"Participants"}],"groups":[{"description":"Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and pazopanib hydrochloride PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nGemcitabine: Given IV\n\nGemcitabine Hydrochloride: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPazopanib: Given PO\n\nPazopanib Hydrochloride: Given PO","id":"BG000","title":"Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride"},{"description":"Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and placebo PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive single-agent pazopanib hydrochloride PO daily. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nGemcitabine: Given IV\n\nGemcitabine Hydrochloride: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPazopanib: Given PO\n\nPazopanib Hydrochloride: Given PO\n\nPlacebo Administration: Given PO","id":"BG001","title":"Gemcitabine Hydrochloride Plus Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"55","upperLimit":"70","value":"63"},{"groupId":"BG001","lowerLimit":"48","upperLimit":"66","value":"56"},{"groupId":"BG002","lowerLimit":"50.3","upperLimit":"68","value":"60"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"30"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"24"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"49"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}],"title":"Unknown/Not Reported"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"16"}]}],"title":"Liposarcoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"14"}]}],"title":"Leiomyosarcoma (LMS)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"}]}],"title":"Undifferentiated Pleomorphic Sarcoma (UPS)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}],"title":"Synovial Sarcoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"10"}]}],"title":"Other Sarcoma(s)"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"3","value":"1"},{"groupId":"BG001","lowerLimit":"1","upperLimit":"3","value":"1"},{"groupId":"BG002","lowerLimit":"1","upperLimit":"3","value":"1"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Number Prior Treatments","unitOfMeasure":"Treatments"}]}